Schott JM - Search Results

1

Biomarkers for Alzheimer's disease beyond amyloid and tau.

Zetterberg H, Schott JM. Zetterberg H, et al. Among authors: schott jm. Nat Med. 2019 Feb;25(2):201-203. doi: 10.1038/s41591-019-0348-z. Nat Med. 2019. PMID: 30728536 No abstract available.

2

New developments in mild cognitive impairment and Alzheimer's disease.

Schott JM, Kennedy J, Fox NC. Schott JM, et al. Curr Opin Neurol. 2006 Dec;19(6):552-8. doi: 10.1097/01.wco.0000247611.44106.76. Curr Opin Neurol. 2006. PMID: 17102693 Review.

3

Using CSF biomarkers to replicate genetic associations in Alzheimer's disease.

Schott JM; ADNI Investigators. Schott JM, et al. Neurobiol Aging. 2012 Jul;33(7):1486.e9-15. doi: 10.1016/j.neurobiolaging.2011.02.008. Epub 2011 Apr 3. Neurobiol Aging. 2012. PMID: 21459483 Free PMC article.

4

Determining cut-points for Alzheimer's disease biomarkers: statistical issues, methods and challenges.

Bartlett JW, Frost C, Mattsson N, Skillbäck T, Blennow K, Zetterberg H, Schott JM. Bartlett JW, et al. Among authors: schott jm. Biomark Med. 2012 Aug;6(4):391-400. doi: 10.2217/bmm.12.49. Biomark Med. 2012. PMID: 22917141 Review.

5

Targeted recruitment using cerebrospinal fluid biomarkers: implications for Alzheimer's disease therapeutic trials.

Barnes J, Bartlett JW, Fox NC, Schott JM. Barnes J, et al. Among authors: schott jm. J Alzheimers Dis. 2013;34(2):431-7. doi: 10.3233/JAD-121936. J Alzheimers Dis. 2013. PMID: 23229078 Clinical Trial.

6

Vascular and Alzheimer's disease markers independently predict brain atrophy rate in Alzheimer's Disease Neuroimaging Initiative controls.

Barnes J, Carmichael OT, Leung KK, Schwarz C, Ridgway GR, Bartlett JW, Malone IB, Schott JM, Rossor MN, Biessels GJ, DeCarli C, Fox NC; Alzheimer's Disease Neuroimaging Initiative. Barnes J, et al. Among authors: schott jm. Neurobiol Aging. 2013 Aug;34(8):1996-2002. doi: 10.1016/j.neurobiolaging.2013.02.003. Epub 2013 Mar 21. Neurobiol Aging. 2013. PMID: 23522844 Free PMC article.

7

Identification of an important potential confound in CSF AD studies: aliquot volume.

Toombs J, Paterson RW, Lunn MP, Nicholas JM, Fox NC, Chapman MD, Schott JM, Zetterberg H. Toombs J, et al. Among authors: schott jm. Clin Chem Lab Med. 2013 Dec;51(12):2311-7. doi: 10.1515/cclm-2013-0293. Clin Chem Lab Med. 2013. PMID: 23940064

8

Biomarker modelling of early molecular changes in Alzheimer's disease.

Paterson RW, Toombs J, Slattery CF, Schott JM, Zetterberg H. Paterson RW, et al. Among authors: schott jm. Mol Diagn Ther. 2014 Apr;18(2):213-27. doi: 10.1007/s40291-013-0069-9. Mol Diagn Ther. 2014. PMID: 24281842 Review.

9

Amyloid-beta 42 adsorption following serial tube transfer.

Toombs J, Paterson RW, Schott JM, Zetterberg H. Toombs J, et al. Among authors: schott jm. Alzheimers Res Ther. 2014 Jan 28;6(1):5. doi: 10.1186/alzrt236. eCollection 2014. Alzheimers Res Ther. 2014. PMID: 24472496 Free PMC article.

10

A data-driven model of biomarker changes in sporadic Alzheimer's disease.

Young AL, Oxtoby NP, Daga P, Cash DM, Fox NC, Ourselin S, Schott JM, Alexander DC; Alzheimer’s Disease Neuroimaging Initiative. Young AL, et al. Among authors: schott jm. Brain. 2014 Sep;137(Pt 9):2564-77. doi: 10.1093/brain/awu176. Epub 2014 Jul 9. Brain. 2014. PMID: 25012224 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

376 results

Search Page

Filters